Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 4-9 , January 2004

Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)

  • Hossein Borghaei

      Affiliations

    • Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • *Address reprint requests to Russell J. Schilder, MD, Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA 19111
    • 1Dr Borghaei serves as a member of the speakers’ list for DesignWright. Dr Schilder receives research grant support from Bristol-Myers Squibb and is a member of the speakers’ bureau for Biogen Idec Inc, OrthoBiotech, and Genentech.
    • ,
  • Russell J. Schilder

      Affiliations

    • Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • 1Dr Borghaei serves as a member of the speakers’ list for DesignWright. Dr Schilder receives research grant support from Bristol-Myers Squibb and is a member of the speakers’ bureau for Biogen Idec Inc, OrthoBiotech, and Genentech.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0001-2998(03)00079-5

doi: 10.1053/j.semnuclmed.2003.11.002

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 4-9 , January 2004

Article Tools

* Image Usage & Resolution